ADAM10 as a Therapeutic Target for Cancer and Inflammation

Author(s): Howard C. Crawford, Peter J. Dempsey, Gordon Brown, Liana Adam, Marcia L. Moss

Journal Name: Current Pharmaceutical Design

Volume 15 , Issue 20 , 2009

Become EABM
Become Reviewer


Both cancer and chronic inflammatory diseases are often marked by homeostatic signal transduction pathways run amok. Cleavage of membrane-bound substrates by extracellular metalloproteinases is frequently the rate limiting step in activating many of these pathways, resulting either in liberation of active ligands (shedding) or initiating further processing into bioactive cytoplasmic domains (regulated intramembrane proteolysis or RIP). ADAM10 is a member of the ADAM (A Disintegrin And Metalloproteinase) family of transmembrane metalloproteinases implicated in the RIPing and shedding of dozens of substrates that drive cancer progression and inflammatory disease, including Notch, E-cadherin, EGF, ErbB2 and inflammatory cytokines. ADAM10s emerging role as a significant contributor to these pathologies has led to intense interest in it as a potential drug target for disease treatment. Here we discuss some of the established functions of ADAM10 and the implications of its inhibition in disease progression.

Keywords: ADAM10, disintegrin, metalloproteinase, inhibition, cancer, inflammation, erbB, Notch, signaling, CD44

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [2288 - 2299]
Pages: 12
DOI: 10.2174/138161209788682442
Price: $65

Article Metrics

PDF: 35